Arena Defends Obesity Drug After Phase III BLOOM Wilts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial